Scaleable glycoproteomic analysis has been stymied in the past by the enormous amount and complexity of the data generated. Manual analysis requires massive amounts of operators’ time to derive interpretable, actionable information, which still does not address issues of accuracy and reproducibility associated with ad-hoc decision making. InterVenn utilizes deep learning to automate the entire workflow, including sample processing, instrument calibration, and peak integration, all the way to run-analysis and results generation.
InterVenn's VISTATM is the first commercially available platform capable of assessing (serum or plasma) protein glycosylation in a site-specific manner, across thousands of peptides and glycopeptides.
Site-specific measurement of protein glycoforms provides unique insights into protein attributes that traditional immunoassays or aptamer-based approaches cannot.
We enable researchers in industry and academia to rapidly and reliably assess glycan-based post-translational modifications (PTMs) at an unprecedented scale and speed without sacrificing resolution and accuracy.See Partner Use Cases Learn More About VISTAtm
Glycoprotein-based liquid biopsy assays provide unprecedented performance in clinical settings. By developing and validating novel markers, we are launching multiple assays that will significantly improve the patient experience by augmenting physician decision-making through novel biological insightsLearn More about the Product Pipelines Learn More about Our VOCAL Trial (Ovarian Cancer)